Next Article in Journal
Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
Next Article in Special Issue
Trospium Chloride Transport by Mouse Drug Carriers of the Slc22 and Slc47 Families
Previous Article in Journal
Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2
Previous Article in Special Issue
Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology
Review

Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts

1
School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute (TBSI), Trinity College Dublin, Dublin 2, Ireland
2
Faculty of Pharmacy, University of Kufa, 540011 Al-Najaf, Iraq
3
Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Department of Translational Pulmonology, University of Heidelberg, 69120 Heidelberg, Germany
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(23), 9168; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239168
Received: 30 October 2020 / Revised: 24 November 2020 / Accepted: 27 November 2020 / Published: 1 December 2020
Organic cation transporters (OCT) 1, 2 and 3 and novel organic cation transporters (OCTN) 1 and 2 of the solute carrier 22 (SLC22) family are involved in the cellular transport of endogenous compounds such as neurotransmitters, l-carnitine and ergothioneine. OCT/Ns have also been implicated in the transport of xenobiotics across various biological barriers, for example biguanides and histamine receptor antagonists. In addition, several drugs used in the treatment of respiratory disorders are cations at physiological pH and potential substrates of OCT/Ns. OCT/Ns may also be associated with the development of chronic lung diseases such as allergic asthma and chronic obstructive pulmonary disease (COPD) and, thus, are possible new drug targets. As part of the Special Issue “Physiology, Biochemistry and Pharmacology of Transporters for Organic Cations”, this review provides an overview of recent findings on the (patho)physiological and pharmacological functions of organic cation transporters in the lung. View Full-Text
Keywords: pulmonary drug delivery; SLC22A1–5; lung epithelium; drug uptake; β2-agonists; chronic lung diseases; anticholinergics pulmonary drug delivery; SLC22A1–5; lung epithelium; drug uptake; β2-agonists; chronic lung diseases; anticholinergics
Show Figures

Figure 1

MDPI and ACS Style

Selo, M.A.; Sake, J.A.; Ehrhardt, C.; Salomon, J.J. Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts. Int. J. Mol. Sci. 2020, 21, 9168. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239168

AMA Style

Selo MA, Sake JA, Ehrhardt C, Salomon JJ. Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts. International Journal of Molecular Sciences. 2020; 21(23):9168. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239168

Chicago/Turabian Style

Selo, Mohammed A., Johannes A. Sake, Carsten Ehrhardt, and Johanna J. Salomon 2020. "Organic Cation Transporters in the Lung—Current and Emerging (Patho)Physiological and Pharmacological Concepts" International Journal of Molecular Sciences 21, no. 23: 9168. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21239168

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop